Boston Biotech Clinical Research
Candida Fratazzi has worked in biomedical research for over 25 years. Prior to her full commitment to Boston Biotech Clinical Research, LLC, she served as Vice President of Clinical Research at MediVector, Inc. Dr. Fratazzi has also held management positions at Johnson & Johnson Pharmaceuticals, Altus Pharmaceuticals Inc., Shire HGT, and Vitex Inc. and Wyeth Pharmaceuticals. During her carrier, Dr. Fratazzi developed clinical strategies and plan developments for many drug candidates, presented in INDs and end-of-phase2 briefing documents. Furthermore, Dr. Fratazzi devoted a special attention to drug safety and risk management recognizing its critical value in the contest of clinical development. Her work resulted in the market approval of TigecyclineÂ® IV (Wyeth), Velaglucerase alphaÂ® (Shire), ReplagalÂ® in Canada, and submission of Lipoprotamase (Alnara).She is also chairman of Women in Bio of Greater Boston.
Personalized Medicine, Clinical research